Astrazeneca (AZN) Depreciation & Amortization (CF) (2009 - 2026)

Astrazeneca's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 6.39% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $5.8 billion (down 13.43% YoY), while the FY2025 annual figure was $5.7 billion, down 14.28% from the prior year.
• Depreciation & Amortization (CF) was $1.4 billion for Q1 2026 at Astrazeneca, down from $1.5 billion in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.3 billion in Q4 2024 to a low of $1.3 billion in Q1 2024.
• Historically, Depreciation & Amortization (CF) has averaged $1.5 billion across 5 years, with a median of $1.4 billion in 2026.
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 107.87% in 2022, then slumped 35.34% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.4 billion in 2022, then decreased by 5.97% to $1.3 billion in 2023, then soared by 83.15% to $2.3 billion in 2024, then plunged by 35.34% to $1.5 billion in 2025, then dropped by 9.6% to $1.4 billion in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.